- 专利标题： Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
-
申请号： US15761398申请日： 2016-09-19
-
公开(公告)号： US11078286B2公开(公告)日： 2021-08-03
- 发明人: Javed Khan , Sivasubramanian Baskar , Rimas J. Orentas , Dimiter S. Dimitrov , Zhongyu Zhu , Tai Chi Cheuk
- 申请人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 申请人地址： US MD Bethesda
- 专利权人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 当前专利权人： The U.S.A., as represented by the Secretary, Department of Health and Human Services
- 当前专利权人地址： US MD Bethesda
- 代理机构： Klarquist Sparkman, LLP
- 国际申请： PCT/US2016/052496 WO 20160919
- 国际公布： WO2017/049296 WO 20170323
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; A61K47/68 ; A61K47/69 ; A61P35/00 ; A61K39/395
摘要：
Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.
公开/授权文献
信息查询
